Published in Clin Cases Miner Bone Metab on January 01, 2011
Association of Blood Biomarkers of Bone Turnover in HIV-1 Infected Individuals Receiving Anti-Retroviral Therapy (ART). J AIDS Clin Res (2015) 0.75
Vitamin D status of human immunodeficiency virus-positive patients with advanced liver disease enrolled in the solid organ transplantation in HIV: multi-site study. Liver Transpl (2013) 0.75
Objective impairments of gait and balance in adults living with HIV-1 infection: a systematic review and meta-analysis of observational studies. BMC Musculoskelet Disord (2017) 0.75
HIV Infection and Bone Abnormalities. Open Orthop J (2017) 0.75
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser (1994) 17.37
A TH1-->TH2 switch is a critical step in the etiology of HIV infection. Immunol Today (1993) 10.43
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA (2004) 10.40
A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS (1998) 8.88
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature (2000) 6.49
Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med (1993) 6.08
Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS (2006) 5.58
IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest (2005) 3.56
Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest (2006) 3.45
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Mitochondrial toxicity of antiviral drugs. Nat Med (1995) 2.83
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr (2009) 2.75
Bone disease and HIV infection. Clin Infect Dis (2005) 2.71
Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20
Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis (2003) 2.20
Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS (2001) 2.17
B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood (2007) 2.16
Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother (1994) 2.10
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis (2009) 2.08
High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses (2009) 2.03
Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS (2008) 2.01
Continuous antiretroviral therapy decreases bone mineral density. AIDS (2009) 1.96
Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS (2007) 1.95
Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS (2003) 1.89
Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr (2010) 1.87
Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS (2003) 1.80
Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab (2006) 1.72
Reduced bone density in HIV-infected women. AIDS (2004) 1.70
OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol (1998) 1.54
Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect (2003) 1.52
Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS (2001) 1.50
Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr (2006) 1.49
BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res (2003) 1.45
Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int (2005) 1.40
HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol (2008) 1.35
Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging (2004) 1.33
Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab (2004) 1.32
Reduced bone mineral density in HIV-positive individuals. AIDS (2001) 1.26
Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS (2001) 1.21
Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem (2002) 1.20
Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials (2003) 1.18
Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone (1995) 1.17
Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther (2006) 1.16
Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab (2009) 1.16
Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol (1998) 1.16
Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr (2005) 1.13
Potential predictive factors of osteoporosis in HIV-positive subjects. Bone (2005) 1.12
Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab (2007) 1.07
HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture. Curr Opin Endocrinol Diabetes Obes (2010) 1.05
Increased expression of suppressor of cytokine signaling-1 (SOCS-1): A mechanism for dysregulated T helper-1 responses in HIV-1 disease. Virology (2009) 0.96
HIV and bone disease. Arch Biochem Biophys (2010) 0.95
A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS (2009) 0.94
Susceptibility of human bone marrow stromal cells to human immunodeficiency virus (HIV). Virology (1995) 0.92
Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials (2004) 0.90
HIV and bone loss. Curr Osteoporos Rep (2010) 0.90
Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients. AIDS (2005) 0.90
Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol (2005) 0.90
Bone loss in patients with HIV infection. Joint Bone Spine (2009) 0.88
Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors. HIV Med (2002) 0.87
Low bone-mineral density in patients with HIV: pathogenesis and clinical significance. Curr Opin Endocrinol Diabetes (2006) 0.85
Osteopenia in patients infected by the human immunodeficiency virus. A case control study. Joint Bone Spine (2002) 0.84
Risk factors of osteopenia in HIV-infected women: no role of antiretroviral therapy. Maturitas (2009) 0.83
Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS (2005) 0.82
Bone mass in HIV-infected patients: focus on the role of therapy and sex. J Acquir Immune Defic Syndr (2003) 0.81
Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses (2006) 0.80
Osteoblasts in HIV-infected patients: HIV-1 infection and cell function. AIDS (2001) 0.80
Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 2.45
Rate of CD4+ cell count increase over periods of viral load suppression: relationship with the number of previous virological failures. Clin Infect Dis (2010) 2.32
Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol (2003) 1.70
Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (2002) 1.52
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels. Clin Infect Dis (2014) 1.47
Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. J Infect Dis (2003) 1.47
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses (2002) 1.45
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. New Microbiol (2015) 1.45
Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis (2004) 1.40
Physician estimates of adherence and the patient-physician relationship as a setting to improve adherence to antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.23
Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol (2005) 1.20
Patient-reported and physician-estimated adherence to HAART: social and clinic center-related factors are associated with discordance. J Gen Intern Med (2004) 1.16
Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. Antivir Ther (2004) 1.07
Impact of metabolic complications on antiretroviral treatment adherence: clinical and public health implications. Curr HIV/AIDS Rep (2009) 1.02
Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood (2002) 1.02
Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients. AIDS Res Hum Retroviruses (2006) 0.99
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. J Antimicrob Chemother (2011) 0.97
Adherence to antiretroviral therapy: where are we, and where do we go from here? J Acquir Immune Defic Syndr (2002) 0.94
Timed short messaging service improves adherence and virological outcomes in HIV-1-infected patients with suboptimal adherence to antiretroviral therapy. J Acquir Immune Defic Syndr (2011) 0.93
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol (2012) 0.93
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol (2011) 0.91
Treatment-related factors and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr (2002) 0.90
Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals. AIDS Patient Care STDS (2008) 0.89
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. J Neurovirol (2005) 0.85
Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. Clin Infect Dis (2003) 0.85
Impact of pre-therapy viral load on virological response to modern first-line HAART. Antivir Ther (2013) 0.84
Sexual dysfunction in HIV infection. Lancet (2007) 0.82
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience. PLoS One (2012) 0.81
HIV-specific CD8 T cells producing CCL-4 are associated with worse immune reconstitution during chronic infection. J Acquir Immune Defic Syndr (2017) 0.80
Inconsistent condom use among HIV-positive women in the "Treatment as Prevention Era": data from the Italian DIDI study. J Int AIDS Soc (2013) 0.79
Switching to Coformulated Rilpivirine/Emtricitabine/Tenofovir in Virologically Suppressed Patients: Data From a Multicenter Cohort. J Acquir Immune Defic Syndr (2015) 0.78
Three-year clinical outcomes of resistance genotyping and expert advice: extended follow-up of the Argenta trial. Antivir Ther (2006) 0.77
Chronic HIV-infected patients show an impaired dendritic cells differentiation of bone marrow CD34⁺ cells. J Acquir Immune Defic Syndr (2013) 0.77
Prevalence of prolonged amenorrhea in HIV-infected women: results from the Italian DIDI study. J Acquir Immune Defic Syndr (2012) 0.77
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. AIDS (2015) 0.76
Oral lesions in HIV and HCV co-infected individuals in HAART era. J Oral Pathol Med (2008) 0.75
Granulocytic Myeloid Derived Suppressor Cells increased in early phases of primary HIV infection depending on TRAIL plasma level. J Acquir Immune Defic Syndr (2017) 0.75
Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patients. AIDS (2004) 0.75
Less drug regimens and PI/r-based strategies in HIV infection: focus on best practices using the HIV patient's journey methodology. New Microbiol (2014) 0.75